| Literature DB >> 30713819 |
Miaoying Yu1,2, Yinghui Wei1, Kui Xu1, Shasha Liu1, Lei Ma1,3, Yangli Pei1, Yanqing Hu1, Zhiguo Liu1, Xue Zhang1, Bingyuan Wang1, Yulian Mu1, Kui Li1.
Abstract
BACKGROUND: Self-renewal and pluripotency are considered as unwavering features of embryonic stem cells (ESCs). How ESCs regulate the self-renewal and differentiation is a central question in development and regenerative medicine research. Epidermal growth factor receptor (EGFR) was identified as a critical regulator in embryonic development, but its role in the maintenance of ESCs is poorly understood.Entities:
Keywords: AG1478; EGFR inhibition; Mouse embryonic stem cells; Pluripotency; Self-renewal
Year: 2019 PMID: 30713819 PMCID: PMC6357870 DOI: 10.7717/peerj.6314
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Figure 1Inhibition of EGFR by AG1478 hinders mESCs proliferation and induces cell cycle arrest at G0/G1 phase.
(A) Control and AG1478 treated mESCs were compared for cell viability by CCK-8. (B and C) Cell cycle phase distribution of control and AG1478 treated mESCs. (D) Quantitative PCR analysis of mRNA levels of cell cycle regulatory genes in control and AG1478 treated mESCs. The amounts of each mRNA were normalized to GAPDH mRNA and are shown relative to the amounts of control mESCs (set to 1). (E) Protein expression of cell cycle regulatory genes (CDK2 and PCNA) in control and AG1478 treated mESCs. β-actin served as a loading control. (F) Quantified relative band intensity ratio of CDK2 and PCNA. The data are presented as mean ± SD (n = 3; *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t-test).
Figure 2Inhibition of EGFR by AG1478 impairs mESC self-renewal and pluripotency, and induces differentiation.
(A) Enzymatic activity for AP was analyzed in control and AG1478 treated mESCs. (B–D) IF staining against SSEA-1 (red), OCT-4 (green), and Nanog (red) in control and AG1478 treated mESCs. Nuclei were counterstained by 4′,6-diamidino-2-phenylindole, scale bar: 200 μm. (E and F) Quantitative PCR analysis of mRNA levels of pluripotency factor s and differentiation related genes in control and AG1478 treated mESCs. The amounts of each mRNA were normalized to GAPDH mRNA and are shown relative to the amounts in control mESCs (set to 1). (G) Protein expression of OCT4 and GATA4 in control and AG1478 treated mESCs. β-actin served as a loading control. (H) Quantified relative band intensity ratio of OCT4 and GATA4. The data are presented as mean ± SD (n = 3; **P < 0.01, ***P < 0.001, Student’s t-test). (I) The performance of EB formation of control and AG1478 treated mESCs, scale bar: 100 μm.
Figure 3Inhibition of EGFR by gefitinib and RNA interference impairs mESCs cell cycle and self-renewal related genes expression.
(A) Protein expression of cell cycle regulatory genes (CDK2 and CDK4), pluripotency factor (OCT4), and differentiation related genes (GATA4 and Notch1) in control and gefitinib treated mESCs. β-actin served as a loading control. (B) Quantified relative band intensity ratio of A. (C) Protein expression of cell cycle regulatory genes (CDK2), pluripotency factor (OCT4), and differentiation related genes (GATA4 and Notch1) in mESCs after RNA interference with different siRNAs. β-actin served as a loading control. (D) Quantified relative band intensity ratio of C. The data are presented as mean ± SD (n = 3; *P < 0.05, **P < 0.01, Student’s t-test).
Figure 4Differentially expressed genes and KEGG pathway enrichment.
(A) Volcano plot of the identified genes in all biological replicates (the genes that showed significant down- and up-regulated after statistical analysis are reported in green and red). (B) Validation of RNA-Seq data by quantitative PCR. Each gene was normalized to GAPDH. Data are presented as the log2 fold change between EGFR inhibition and control mESCs. (C) Scatter plot of top 20 KEGG enrichments of mRNA. Vertical coordinate represents pathway name, and horizontal coordinate represents Rich factor. The size and color of points represent the number of differentially expressed genes in the pathway and the range of different corrected P-values, respectively.
Self-renewal and pluripotency related GO categories significantly enriched from DEGs between two mESCs groups.
| GO ID | GO category | Description | Corrected |
|---|---|---|---|
| Biological process | Cell cycle | 3.14 | |
| Biological process | Cell cycle checkpoint | 3.75 | |
| Biological process | Cell cycle phase | 1.75 | |
| Biological process | Cell cycle phase transition | 3.22 | |
| Biological process | Cell cycle process | 2.51 | |
| Biological process | Mitotic cell cycle | 3.99 | |
| Biological process | Mitotic cell cycle checkpoint | 2.01 | |
| Biological process | Mitotic cell cycle phase transition | 3.55 | |
| Biological process | Negative regulation of cell cycle | 0.001747 | |
| Biological process | Negative regulation of cell cycle phase transition | 1.72 | |
| Biological process | Negative regulation of cell cycle process | 2.93 | |
| Biological process | Regulation of cell cycle | 7.67 | |
| Biological process | Regulation of cell cycle phase transition | 1.06 | |
| Biological process | Regulation of mitotic cell cycle | 2.24 | |
| Biological process | Regulation of mitotic cell cycle phase transition | 9.37 | |
| Biological process | G1/S transition of mitotic cell cycle | 0.000163 | |
| Biological process | Positive regulation of cell cycle phase transition | 0.003147 | |
| Biological process | Positive regulation of cell cycle process | 0.000392 | |
| Biological process | Apoptotic process | 2.38 | |
| Biological process | Regulation of apoptotic process | 2.31 | |
| Biological process | Apoptotic signaling pathway | 2.77 | |
| Biological process | Negative regulation of apoptotic process | 0.0034509 | |
| Biological process | Stem cell maintenance | 0.012077 | |
| Cellular component | Cell division site | 0.0080312 | |
| Cellular component | Cell division site part | 0.0080312 | |
| Cellular component | Condensed chromosome | 1.28 | |
| Cellular component | Condensed chromosome kinetochore | 2.33 | |
| Cellular component | Condensed chromosome, centromeric region | 1.56 | |
| Cellular component | Condensed nuclear chromosome | 1.62 | |
| Cellular component | Condensed nuclear chromosome, centromeric region | 0.00080836 | |
| Cellular component | Histone acetyltransferase complex | 0.00053467 | |
| Cellular component | Histone methyltransferase complex | 3.66 | |
| Cellular component | Mitochondrial part | 1.04 | |
| Cellular component | Nuclear heterochromatin | 0.00039438 | |
| Cellular component | PcG protein complex | 0.008405 | |
| Cellular component | Adherens junction | 1.40 | |
| Molecular function | Chromatin binding | 2.39 | |
| Molecular function | Chromatin DNA binding | 0.0025282 | |
| Molecular function | Histone binding | 8.38 | |
| Molecular function | Histone demethylase activity (H3-K4 specific) | 0.037622 | |
| Molecular function | Histone acetyltransferase activity | 0.019528 | |
| Molecular function | Histone acetyltransferase activity (H4-K16 specific) | 0.015756 | |
| Molecular function | Histone acetyltransferase activity (H4-K5 specific) | 0.015756 | |
| Molecular function | Histone acetyltransferase activity (H4-K8 specific) | 0.015756 | |
| Molecular function | Transcription factor binding | 0.0044703 |
Notes:
The details of the table are described below: (1) GO ID: the unique id in gene ontology database; (2) GO category: type of the GO term (cellular component, biological process, or molecular function); (3) description: function description in gene ontology; (4) corrected P-value: statistical significance on enrichment with correction.
Self-renewal and pluripotency related KEGG pathways significantly enriched from DEGs between two mESCs groups.
| KEGG ID | KEGG term description | Corrected |
|---|---|---|
| mmu04110 | Cell cycle | 6.98 |
| mmu04115 | p53 signaling pathway | 0.008629188 |
| mmu03030 | DNA replication | 1.73 |
| mmu03010 | Ribosome | 5.67 |
| mmu03008 | Ribosome biogenesis in eukaryotes | 2.00 |
| mmu03040 | Spliceosome | 7.14 |
| mmu03015 | mRNA surveillance pathway | 0.000343 |
| mmu03013 | RNA transport | 1.66 |
| mmu03018 | RNA degradation | 0.001903 |
| mmu01100 | Metabolic pathways | 2.00 |
| mmu00240 | Pyrimidine metabolism | 1.25 |
| mmu00190 | Oxidative phosphorylation | 4.13 |
| mmu00020 | Citrate cycle (TCA cycle) | 0.001666 |
| mmu01200 | Carbon metabolism | 3.66 |
Notes:
The details of the table are described below: (1) KEGG ID: unique pathway id in the KEGG database; (2) KEGG term description: function description of the KEGG pathway; (3) Corrected P-value: statistical significance of the enrichment with correction.